阿托伐他汀治疗动脉硬化性脑梗死的临床价值分析

谷欣荣，张晓中，王积贵

（宁强县天津医院神经内科，陕西 汉中，724400）

浏览次数：73次 下载次数：344次

摘要：

目的 分析阿托伐他汀在动脉硬化性脑梗死患者治疗中的临床价值。方法 选择我院收治的100例动脉硬化性脑梗死患者作为研究对象，随机分成观察组与对照组，各50例。对照组采用常规治疗，观察组在常规治疗的基础上加用阿托伐他汀。比较两组的临床疗效、炎症因子及血脂水平。结果 观察组患者的治疗总有效率为94.00%，明显高于对照组的68.00%（P<0.05）。治疗后，两组患者IL-6 及hs-CRP水平均显著低于治疗前，且观察组明显低于对照组（P<0.05）。治疗后，观察组患者的TC、TG、LDL-C水平均显著低于对照组，而HDL-C水平高于对照组（P<0.05）。结论 动脉硬化性脑梗死患者采用阿托伐他汀治疗临床效果显著，可明显改善患者的临床症状，具有较高的临床应用价值。

关键词：阿托伐他汀；动脉硬化；脑梗死；炎症因子；血脂水平

中图分类号：R743.33文献标志码：A文章编号：2096-1413(2017)22-0073-02

Clinical value of atorvastatin in the treatment of patients with arteriosclerosis cerebral infarction
GU Xin-rong, ZHANG Xiao-zhong, WANG Ji-gui
(Department of Neurology, Tianjin Hospital of Ningqiang County, Hanzhong 724400, China)

ABSTRACT: Objective To analyze the clinical value of atorvastatin in the treatment of patients with arteriosclerosis cerebral infarction. Methods One hundred cases of patients with arteriosclerosis cerebral infarction admitted in our hospital were randomly divided into observation group and control group, with 50 cases in each group. The control group took conventional treatment and the observation group received atorvastatin on the basis of the control group. The clinical efficacy, inflammatory factor and blood lipid levels of two groups were compared. Results The total effective rate of treatment in the observation group was 94.00%, which was significantly higher than 68.00% of the control group (P<0.05). After treatment, the levels of IL-6 and hs-CRP in the two groups were significantly lower than those before treatment and those in the observation group was lower than the control group (P<0.05). After treatment, the levels of TC, TG, LDLD-C in
the observation group were significantly lower than those of the control group, while the HDL-C level was higher than that of the control group (P<0.05). Conclusion Atorvastatin for patients with arteriosclerosis cerebral infarction has significant clinical effects, which can obviously improve clinical symptoms, the inflammatory factor and blood lipid levels, it has high clinical application value.
KEYWORDS: atorvastatin; arteriosclerosis; cerebral infarction; inflammatory factor; blood lipid level

参考文献：
[1] 何永利,黄廷富,潘小平.阿托伐他汀对急性脑梗死患者血清心肌型脂肪酸结合蛋白和氧化型低密度脂蛋白水平的影响[J].中国动脉硬化杂志,2015,23(8):834-836.
[2] 傅亚明.阿托伐他汀改善动脉硬化性脑梗死患者血脂与神经功能的临床研究[J].中国慢性病预防与控制,2014,22(1):101-102.
[3] 张彦海,胡小菁,刘养凤,等.黄连素联合阿托伐他汀治疗脑梗死患者的研究[J].实用医院临床杂志,2014,11(2):80-83.
[4] 黄兆仙,李婷婷.颈动脉硬化斑块与脑梗死的相关性研究[J].中国中西医结合影像学杂志,2016,14(3):246-247,251.
[5] 苏丹丹,肖波,毕方方.阿托伐他汀钙治疗急性脑梗死的有效剂量、最适剂量及安全性研究[J].河北医药,2016,38(16):2450-2452.
[6] 徐文苑,黄经纬,徐仁伵,等.急性动脉硬化性脑梗死患者颅内动脉狭窄的危险因素分析[J].中国临床神经科学,2016,24(2):186-193.
[7] 方圆,李晓晖,方建,等.颈动脉粥样硬化对脑梗死复发的影响及应用阿托伐他汀钙的作用[J].中国实用神经疾病杂志,2013,16(7):32-34.
[8] 梅赈,陈力超.阿托伐他汀联合脑心通胶囊治疗脑梗死并颈动脉粥样硬化的临床研究[J].中国基层医药,2013,20(3):391-393.